SAAP 148 TFA

SAAP 148 TFA kills ≥99.9% of planktonic Staphylococcus aureus JAR060131 with an LC_99.9 of 1.6 μM in PBS and 12.8 μM in PBS with 50% human plasma^[1].
SAAP 148 TFA kills ≥99.9% of planktonic Pseudomonas aeruginosa PAO1 with an LC_99.9 of 1.6 μM in PBS and 12.8 μM in PBS with 50% human plasma^[1].
SAAP 148 (1.6-12.8 μM; 24 hours) TFA dose-dependently prevents biofilm formation by Staphylococcus aureus JAR060131, Acinetobacter baumannii RUH875, and both ica-dependent and ica-independent Staphylococcus epidermidis O-47^[1].
SAAP 148 (1.6-102.4 μM; 2 hours) TFA dose-dependently eradicates established biofilms of Staphylococcus aureus JAR060131, Acinetobacter baumannii RUH875, and both ica-dependent and ica-independent Staphylococcus epidermidis O-47^[1].
SAAP 148 (1.6-3.2 μM; 2-4 hours) TFA completely eradicates Staphylococcus aureus JAR060131 persister cells^[1].
SAAP 148 (0.4-3.2 μM; 0.5-120 minutes) TFA rapidly permeabilizes the membranes of Staphylococcus aureus JAR060131 and Acinetobacter baumannii RUH875, leading to complete bacterial killing^[1].
SAAP 148 (0.125-4 μM) TFA strongly perturbs the hydrophobic core of bacterial cytoplasmic membrane-mimicking liposomes and induces complete fluorochrome leakage from POPG liposomes at concentrations ≥2 μM^[1].
SAAP 148 TFA exhibits bactericidal activity against MRSA LUH14616, but its bactericidal efficacy is reduced by interaction with precipitated proteins in plasma or eschar extracts^[3].
SAAP 148 TFA preincubation of SAAP-148 with Novomaix collagen-elastin 3D matrix for 24 h reduces bactericidal activity against MRSA LUH14616, while preincubation with 3% BSA causes an immediate, sustained reduction in efficacy^[3].
SAAP 148 (0-100 nmol; 1 h) TFA induces dose-dependent cytotoxicity in 2D-cultured human fibroblasts and keratinocytes, with 0.23 nmol causing 50% LDH release after 1 h incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.